Content

1. 9th PharmaMed 2026 to be held at New Delhi
2. Cabinet approves India’s Nationally Determined Contribution (2031-2035) to be communicated to the United Nations Framework Convention on Climate Change

9th PharmaMed 2026 to be held at New Delhi

Issue in Brief

• 9th PharmaMed 2026 in New Delhi convenes policymakers, regulators, and industry leaders to deliberate India’s pharmaceutical transition towards innovation-driven, equitable, and globally competitive healthcare ecosystem aligned with Viksit Bharat 2047 vision.
• Conference emphasises regulatory harmonisation, quality assurance, innovation, and last-mile access, reflecting India’s dual challenge of sustaining global generic leadership while ensuring affordable medicines for its 1.4 billion population.

Relevance

• GS II (Governance & Health):
  • Drug regulation (Central Drugs Standard Control Organization), affordability (National Pharmaceutical Pricing Authority), Right to Health (Art. 21).
  • Role of schemes like PM Bhartiya Janaushadhi Pariyojana in Universal Health Coverage.
• GS III (Economy & S&T):
  • Pharma industry growth (~USD 50B → USD 130B by 2030), global generics leadership.
  • API dependence (~65% imports) → supply chain vulnerability.
  • Innovation gap (R&D 8–10% vs global 15–20%).

Practice Question

Q1.“India’s pharmaceutical sector faces a paradox of global scale but limited innovation.”
Analyse the structural constraints and suggest policy reforms. (250 words)

Institutional Background

• India’s pharma sector regulated under Drugs and Cosmetics Act, 1940, with Central Drugs Standard Control Organization ensuring drug safety, efficacy, and quality through approvals, licensing, and post-marketing surveillance mechanisms.
• National Pharmaceutical Policy, 2012 and Drug Price Control Order (DPCO) operationalised via National Pharmaceutical Pricing Authority ensure affordability, covering 800+ essential drugs under price control to promote healthcare equity.
• India is 3rd largest pharma producer by volume and 14th by value, supplying 20% of global generics and 60% of vaccines, indicating strong scale but limited value addition.

Multi-Dimensional Analysis

Constitutional / Legal

• Article 21 (Right to Life) includes right to health and access to medicines, reinforced in Paschim Banga case, obligating state to ensure timely and affordable healthcare delivery.
• India’s TRIPS compliance balances patent protection and public health, using compulsory licensing to ensure availability of essential medicines in public interest, especially during health emergencies.

Governance / Administrative

• Regulatory fragmentation between CDSCO and State Drug Controllers leads to uneven enforcement capacity, necessitating harmonised digital regulatory architecture for uniform drug quality standards.
• PLI Schemes for APIs and bulk drugs aim to reduce ~65% import dependence on China, strengthening supply chain resilience and advancing Atmanirbhar Bharat objectives.

Economic

• Indian pharma industry valued at ~USD 50 billion (2023), projected to reach ~USD 130 billion by 2030, driven by exports, generics demand, and emerging biologics and biosimilars segments.
• Low-margin generic dominance limits profitability; India spends only 8–10% of revenue on R&D compared to 15–20% globally, constraining shift towards innovation-led value chain.

Social / Ethical

• Out-of-pocket expenditure ~48% of total health spending (National Health Accounts), making affordable medicines critical to reduce catastrophic expenditure and achieve Universal Health Coverage (UHC).
• Persistent urban-rural disparities in access, with rural areas lacking pharmacies and logistics, requiring expansion of Jan Aushadhi Kendras and digital health platforms for last-mile delivery.

Environment / Security / Tech

• API manufacturing contributes to chemical pollution, requiring stricter environmental compliance and green chemistry practices for sustainable pharmaceutical growth.
• Counterfeit drugs (~3–5% of market) pose serious public health risks; adoption of blockchain, QR-based track-and-trace systems essential for supply chain integrity.
• Growth of e-pharmacies and telemedicine under Ayushman Bharat Digital Mission (ABDM) enhances access but raises concerns on data privacy, cybersecurity, and ethical governance.

 Data & Evidence

• India exports medicines to 200+ countries, with exports worth ~USD 27 billion (2023), reinforcing its role as “Pharmacy of the World” (Economic Survey).
• PM Bhartiya Janaushadhi Pariyojana (PMBJP) operates 18,000+ stores, offering medicines at 50–90% lower prices, significantly improving affordability for economically weaker sections.

 Challenges / Criticism

• Regulatory capacity gaps and uneven enforcement affect drug quality perception, leading to compliance issues with stringent regulators like USFDA and EMA.
• High API import dependence (~65%) exposes India to geopolitical risks and supply disruptions, as seen during COVID-19 pandemic.
• Weak innovation ecosystem due to low R&D investment, limited industry-academia collaboration, and regulatory delays hampers growth in high-value segments like biologics.
• Ethical concerns such as aggressive pharma marketing, prescription bias, and data misuse undermine patient trust and transparency in healthcare delivery.

Way Forward

• Establish “One Nation–One Drug Regulator” through digital integration of CDSCO and state regulators for uniform standards, faster approvals, and improved compliance monitoring.
• Boost R&D investment via ICMR, BIRAC funding, tax incentives, and innovation clusters, focusing on biologics, vaccines, and precision medicine.
• Expand PM Jan Aushadhi network and integrate with ABDM to ensure affordable, accessible medicines through digital prescriptions and last-mile delivery.
• Strengthen API self-reliance through expanded PLI schemes, bulk drug parks, and strategic reserves of critical inputs.
• Implement end-to-end drug traceability (QR/blockchain) to curb counterfeit medicines and ensure global compliance standards.
• Enforce Uniform Code of Pharmaceutical Marketing Practices (UCPMP) strictly to ensure ethical governance and transparency in doctor-industry interactions.

Prelims Pointers

• CDSCO functions under Ministry of Health and Family Welfare, not Chemicals and Fertilizers.
• NPPA implements DPCO, not CDSCO.
• India is 3rd by volume, 14th by value in pharma production globally.
• PMBJP provides generic medicines at subsidised rates through government-supported outlets.

Cabinet approves India’s Nationally Determined Contribution (2031-2035) to be communicated to the United Nations Framework Convention on Climate Change

Why in News ?

• Union Cabinet approval on 25 March 2026 for India’s NDC (2031–2035) to be submitted to United Nations Framework Convention on Climate Change, marking next cycle of Paris Agreement commitments.
• India enhanced targets to 47% emissions intensity reduction, 60% non-fossil capacity, and 3.5–4 billion tonnes carbon sink by 2035, signalling post-2030 ambition escalation beyond earlier commitments.

Relevance

• GS II (International Relations):
  • India’s commitments under Paris Agreement via UNFCCC.
  • Climate justice, CBDR-RC principle.
• GS III (Environment & Economy):
  • Targets: 47% emission intensity reduction, 60% non-fossil capacity, 3.5–4 billion tonnes carbon sink.
  • Renewable transition, green hydrogen, carbon markets.
• GS III (Internal Security / Energy):
  • Reduced fossil dependence → energy security.

Practice Question

Q1.India’s updated Nationally Determined Contributions reflect a balance between development and climate responsibility. Critically analyse. (250 words)

Issue in Brief

• India commits to 47% reduction in emissions intensity of GDP by 2035 (base year: 2005), compared to earlier 45% target for 2030 (updated NDC 2022).
• New targets include 60% installed electricity capacity from non-fossil sources by 2035 and 3.5–4 billion tonnes CO₂ equivalent carbon sink, strengthening pathway to Net-Zero by 2070.

Institutional Background

• NDCs are submitted under Paris Agreement (2015), operationalised through UNFCCC, based on principle of CBDR-RC (equity + differentiated responsibility).
• India’s original NDC (2015):
  • 33–35% emissions intensity reduction by 2030
  • 40% non-fossil capacity
  • 2.5–3 billion tonnes carbon sink
• Updated NDC (Aug 2022) raised ambition to:
  • 45% emissions intensity reduction by 2030
  • 50% non-fossil capacity by 2030

Data-Based Progress (Before New NDC)

• Emission intensity already reduced by ~33% (2005–2019) and further to ~36% by 2020, indicating early progress towards targets.
• India achieved 50% non-fossil installed capacity in June 2025, 5 years ahead of 2030 target, demonstrating accelerated clean energy transition.
• Non-fossil capacity reached 52.57% (Feb 2026), exceeding earlier commitments and justifying upward revision of targets.

Multi-Dimensional Analysis

 Constitutional / Legal

• Article 48A and 51A(g) provide constitutional mandate for environmental protection, forming legal basis for India’s enhanced climate commitments and sustainable development trajectory.
• India’s NDC reflects climate justice approach, ensuring development space while contributing to global mitigation under Paris Agreement obligations without legally binding emission caps.

Governance / Administrative

• NDC prepared through 10 sectoral working groups under NITI Aayog, ensuring whole-of-government and stakeholder consultation approach across energy, transport, agriculture, and industry sectors.
• Implemented via NAPCC + SAPCCs + flagship schemes, ensuring vertical and horizontal policy convergence across Union and State levels for climate governance.

Economic

• Transition to 60% non-fossil capacity by 2035 requires massive investments in renewables, storage, green hydrogen, and grid infrastructure, driving green growth and employment.
• India demonstrates decoupling of GDP growth from emissions, as economy expands while emission intensity declines, reinforcing sustainable development model.

Social / Ethical

• Focus on just transition ensures protection of coal-dependent regions, farmers, and vulnerable populations, aligning climate action with equity and livelihood security.
• Behavioural initiatives like Mission LiFE transform climate action into mass movement, integrating sustainability into everyday consumption patterns.

Environment / Security / Tech

• Expansion of renewables reduces fossil fuel import dependence, enhancing energy security and reducing current account pressures.
• Adaptation measures include mangrove restoration, glacier monitoring, Heat Action Plans, and early warning systems, addressing rising climate risks like heatwaves and floods.
• Deployment of green hydrogen, CCUS, battery storage, and nuclear energy strengthens low-carbon industrial ecosystem and technological competitiveness.

Data & Evidence

• India created 2.29 billion tonnes CO₂ equivalent carbon sink by 2021, progressing towards enhanced 3.5–4 billion tonnes target by 2035.
• Ranked 3rd globally in net forest area gain (FAO), reflecting success of afforestation and ecosystem restoration initiatives.

Challenges / Criticism

• Energy mix still dominated by coal (~70% electricity generation), making deep decarbonisation structurally difficult while ensuring energy security.
• Climate finance gap persists, with developed countries failing to fully deliver $100 billion/year commitment, affecting developing countries’ transition capacity.
• Technological limitations in storage, CCUS, and green hydrogen scalability constrain pace of achieving ambitious non-fossil targets.
• Balancing development priorities (poverty alleviation, infrastructure expansion) with climate commitments raises concerns of equity and implementation feasibility.

Way Forward

• Accelerate renewable capacity addition with storage integration and modernise grid infrastructure to ensure reliability of 60% non-fossil energy target.
• Leverage international platforms like ISA, CDRI, GBA to secure climate finance, technology transfer, and global partnerships.
• Expand nature-based solutions (afforestation, mangroves, ecosystem restoration) to achieve carbon sink targets while enhancing biodiversity and livelihoods.
• Develop domestic carbon markets and pricing frameworks to incentivise industries for emission reductions and energy efficiency improvements.
• Strengthen urban climate planning, water management, and agriculture resilience to integrate adaptation into development planning.
• Institutionalise Mission LiFE for behavioural change, ensuring citizen-led sustainability transition.

Prelims Pointers

• NDCs are voluntary national commitments, not legally binding emission targets under Paris Agreement.
• CBDR-RC principle = differentiated responsibility based on historical emissions and capacity.
• India’s Net-Zero target: 2070, not 2050.
• Updated NDC 2022 targets: 45% emissions intensity + 50% non-fossil capacity by 2030.